1.This Act may be cited as the
Alzheimer’s Breakthrough Act of
2007
.
2.Congress makes the following
findings:
(1)Alzheimer's
disease is a disorder that destroys cells in the brain. The disease is the
leading cause of dementia, a condition that involves gradual memory loss,
decline in the ability to perform routine tasks, disorientation, difficulty in
learning, loss of language skills, impairment of judgment, and personality
changes. As the disease progresses, people with Alzheimer's disease become
unable to care for themselves. The loss of brain cells eventually leads to the
failure of other systems in the body.
(2)An estimated
4,500,000 Americans have Alzheimer's disease and 1 in 10 individuals have a
family member with the disease. By 2050, the number of individuals with the
disease could range from 13,000,000 to 16,000,000 unless science finds a way to
prevent or cure the disease.
(3)One in 10 people
over the age of 65, and nearly half of those over the age of 85 have
Alzheimer's disease. Younger people also get the disease.
(4)The Alzheimer's
disease process may begin in the brain as many as 20 years before the symptoms
of Alzheimer's disease appear. An individual will live an average of 8 years
and as many as 20 once the symptoms of Alzheimer's disease appear.
(5)The average
lifetime cost of care for an individual with Alzheimer's disease is
$170,000.
(6)In 2005, Medicare
alone spent $91,000,000,000 for the care of individuals with Alzheimer's
disease and this amount is projected to increase to $160,000,000,000 in
2010.
(7)Ninety-five
percent of Medicare beneficiaries with Alzheimer’s disease have one or more
other chronic conditions that are common in the elderly, coronary heart disease
(30 percent), congestive heart failure (28 percent), diabetes (21 percent), and
chronic obstructive pulmonary disease (17 percent).
(8)Seven in 10
individuals with Alzheimer's disease live at home. While almost 75 percent of
home care is provided by family and friends, the average annual cost of paid
care for people with Alzheimer's disease at home is $19,000 per year. Almost
all families pay this cost out of pocket.
(9)Half of all
nursing home residents have Alzheimer's disease or a related disorder. The
average annual cost of Alzheimer's disease nursing home care is more than
$70,000. Medicaid pays half of the total nursing home bill and helps 2 out of 3
residents pay for their care. Medicaid expenditures for nursing home care for
people with Alzheimer's disease are estimated to increase from $21,000,000,000
in 2005 to $24,000,000,000 in 2010.
(10)In fiscal year
2007, the Federal Government will spend an estimated $642,000,000 on
Alzheimer's disease research. If the United States achieves its research goals
(preventing the onset of Alzheimer's disease in those at risk and treating and
delaying progression of the disease in those who have symptoms), annual
Medicare savings would be $51,000,000,000 by 2015 and $88,000,000,000 by 2020.
Annual Medicaid savings would be $10,000,000,000 in 2015 and $17,000,000,000 by
2020 and the projected number of cases of Alzheimer's disease can be reduced by
40 percent by the middle of the century.
(11)An analysis by
the Montefiore Medical Center and the Albert Einstein College of Medicine
estimated that the annual value of the informal care system is
$306,000,000,000. Family caregiving comes at enormous physical, emotional, and
financial sacrifice, putting the whole system at risk.
(12)One in 8
Alzheimer's disease caregivers becomes ill or injured as a direct result of
caregiving. One in 3 uses medication for problems related to caregiving. Older
caregivers are 3 times more likely to become clinically depressed than others
in their age group.
(13)Elderly spouses
strained by caregiving are 63 percent more likely to die during a given 4-year
period than other spouses their age.
(14)Almost 3 of 4
caregivers are women. One in 3 has children or grandchildren under the age of
18 living at home. Caregiving leaves them less time for other family members
and they are much more likely to report family conflicts because of their
caregiving role.
(15)Most Alzheimer's
disease caregivers work outside the home before beginning their caregiving
careers, but caregiving forces them to miss work, cut back to part-time, take
less demanding jobs, choose early retirement, or give up work altogether. As a
result, in 2002, Alzheimer's disease cost American business an estimated
$36,500,000,000 in lost productivity, as well as an additional $24,600,000,000
in business contributions to the total cost of care.
<enum>I</enum><header>Increasing the
Federal commitment to alzheimer’s research</header>
<section id="ID51C890178EED4F879E6C5490BA854F0D"><enum>101.</enum><header>Doubling nih
funding for Alzheimer’s disease research</header>
<subsection id="IDEC90B153598C4F73BB51CFCEE442B6AF"><enum>(a)</enum><header>In
General</header><text>For the purpose of conducting and supporting research on
Alzheimer’s disease (including related activities under subpart 5 of part C of
title IV of the <act-name parsable-cite="PHSA">Public Health Service
Act</act-name> (42 U.S.C. 285e et seq.) there is authorized to be appropriated
$1,300,000,000 for fiscal year 2008, and such sums as may be necessary for each
of fiscal years 2009 through 2012.</text>
</subsection><subsection id="ID538D0FFAEF594794A06535A040018105"><enum>(b)</enum><header>Aging Process
Regarding Women</header><text>Section 445H(b) of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–10(b)) is amended by striking <quote>2003</quote> and inserting
<quote>2012</quote>.</text>
</subsection><subsection id="IDFA3E75BDB3AA49A088B0F5D5635A7954"><enum>(c)</enum><header>Clinical
Research and Training Awards</header><text>Section 445I(d) of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–10a(d)) is amended by striking <quote>2005</quote> and inserting
<quote>2012</quote>.</text>
</subsection></section><section id="ID0804D572DC494E0F9FF05C6553738017"><enum>102.</enum><header>Priority to
Alzheimer’s disease research</header><text display-inline="no-display-inline">Section 443 of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e) is amended—</text>
<paragraph id="ID33D514AD5E324665A9A6111D178803D0"><enum>(1)</enum><text>by striking
<quote>The general</quote> and inserting <quote>(a) <header-in-text>In
General</header-in-text>.—The general</quote>; and</text>
</paragraph><paragraph id="ID8EFE4105E9DB46FEA4CA7B576467CEAB"><enum>(2)</enum><text>by adding at the
end the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" id="IDBA8488AA5CEC4505AF983BDBE70DE408" reported-display-style="strikethrough" style="OLC">
<subsection id="ID48F1F19DCDDC4861B9054C1042DA6928"><enum>(b)</enum><header>Priorities</header><text>The
Director of the Institute shall, in expending amounts appropriated under this
subpart, give priority to conducting and supporting Alzheimer’s disease
research.</text>
</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
</paragraph></section><section id="id852DBBFC34634F05B50D3B0211E87DED"><enum>103.</enum><header>Alzheimer's
disease prevention initiative</header><text display-inline="no-display-inline">Section 443 of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e), as amended by section 102, is further amended by adding at the end the
following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="id91ACFF487EDD4E77958ED1F8B461612E" reported-display-style="strikethrough" style="OLC">
<subsection id="id32B79284591A4FD6B1F1D6FC57EC15DB"><enum>(c)</enum><header>Prevention
trials</header><text>The Director of the Institute shall increase the emphasis
on the need to conduct Alzheimer's disease prevention trials within the
National Institutes of Health.</text>
</subsection><subsection id="idECF35CFD8D7D47CBB709A597628FCF54"><enum>(d)</enum><header>Neuroscience
initiative</header><text>The Director of the Institute shall ensure that
Alzheimer’s disease is maintained as a high priority for the existing
neuroscience
initiative.</text>
</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
</section><section id="ID0FC9B196B54C42C3BD51E29B70560897"><enum>104.</enum><header>Alzheimer’s
disease clinical research</header>
<subsection id="ID7D1489A4A60B47CF82CAF8E453EB8F28"><enum>(a)</enum><header>Clinical
Research</header><text>Subpart 5 of part C of title IV of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e et seq.) is amended by adding at the end the following:</text>
<quoted-block act-name="Public Health Service Act" changed="deleted" committee-id="SSHR00" id="ID4B90943A185C43E3BCE2218A453AB1D7" reported-display-style="strikethrough" style="OLC">
<section id="IDD17AA655BD7D4C4F9D2C8F0B463D0BA3"><enum>445J.</enum><header>Alzheimer’s
disease clinical research</header>
<subsection id="ID4392D9B1305E4CD3A4FE9FC2AD7EDB6D"><enum>(a)</enum><header>In
General</header><text>The Director of the Institute, pursuant to subsections
(d) and (e) of section 444, shall conduct and support cooperative clinical
research regarding Alzheimer’s disease. Such research shall include—</text>
<paragraph id="ID032AC873B88843079872655EB2DB030D"><enum>(1)</enum><text>investigating
therapies, interventions, and agents to detect, treat, slow the progression of,
or prevent Alzheimer’s disease;</text>
</paragraph><paragraph id="ID90B7277CA08244509B076282B1DFBCEC"><enum>(2)</enum><text>enhancing the
national infrastructure for the conduct of clinical trials;</text>
</paragraph><paragraph id="IDB6000EB3E34B41B8A0462F48B79CA959"><enum>(3)</enum><text>developing and
testing novel approaches to the design and analysis of such trials;</text>
</paragraph><paragraph id="ID784A2AF7B106402C9093AD8A3DBE4999"><enum>(4)</enum><text>facilitating the
enrollment of patients for such trials, including patients from diverse
populations;</text>
</paragraph><paragraph id="ID1DBAFD4ECAE04F999D8C6967FA8F1E06"><enum>(5)</enum><text>developing
improved diagnostics and means of patient assessment for Alzheimer’s
disease;</text>
</paragraph><paragraph id="ID7cf393ef59514a30a734c8ccd94a6e96"><enum>(6)</enum><text>the conduct of
clinical trials on potential therapies, including readily available compounds
such as herbal remedies and other alternative treatments;</text>
</paragraph><paragraph id="ID628b7764f6d941c6a0a794cfbf204af6"><enum>(7)</enum><text>research to
develop better methods of early diagnosis, including the use of current imaging
techniques; and</text>
</paragraph><paragraph id="ID80DB4B9A23E3451E9D0D6119BEB274EF"><enum>(8)</enum><text>other research as
determined appropriate by the Director of the Institute, the Alzheimer’s
Disease Centers and Alzheimer’s Disease Research Centers established under
section 445.</text>
</paragraph></subsection><subsection id="ID5ADDACA86EDF4777B6ED5EA9FAED8B5A"><enum>(b)</enum><header>Early Diagnosis
and Detection Research</header>
<paragraph id="IDE5EBF5DAD0F14DFB9490FEAFB979FF5D"><enum>(1)</enum><header>In
general</header><text>The Director of the Institute, in consultation with the
directors of other relevant institutes and centers of the National Institutes
of Health, shall conduct, or make grants for the conduct of, research related
to the early detection, diagnosis, and prevention of Alzheimer’s disease and of
mild cognitive impairment or other potential precursors to Alzheimer’s
disease.</text>
</paragraph><paragraph id="ID1FBFDAD51F934A60B07276E39C207073"><enum>(2)</enum><header>Evaluation</header><text>The
research described in paragraph (1) may include the evaluation of diagnostic
tests and imaging techniques.</text>
</paragraph><paragraph id="ID15e4672d37e1410198ad5d83b1bdcc58"><enum>(3)</enum><header>Study</header><text>Not
later than 1 year after the date of enactment of this section, the Director of
the Institute, in cooperation with the heads of other relevant Federal
agencies, shall conduct a study, and submit to Congress a report, to estimate
the number of individuals with early-onset Alzheimer’s disease (those diagnosed
before the age of 65) and related dementias in the United States, the causes of
early-onset dementia, and the unique problems faced by such individuals,
including problems accessing government services.</text>
</paragraph></subsection><subsection id="IDE045CB5544DA483388D574609AD55538"><enum>(c)</enum><header>Vascular
Disease</header><text>The Director of the Institute, in consultation with the
directors of other relevant institutes and centers of the National Institutes
of Health, shall conduct, or make grants for the conduct of, research related
to the relationship of vascular disease and Alzheimer’s disease, including
clinical trials to determine whether drugs developed to prevent cerebrovascular
disease can prevent the onset or progression of Alzheimer’s disease.</text>
</subsection><subsection id="id32C3092F42E746868CE4AC05B4C979E3"><enum>(d)</enum><header>Treatments and
prevention</header><text>The Director of the Institute shall place special
emphasis on expediting the translation of research findings under this section
into effective treatments and prevention strategies for at-risk
individuals.</text>
</subsection><subsection id="ID5E72766343C94BFB94771274C8FA604A"><enum>(e)</enum><header>National
Alzheimer’s Coordinating Center</header><text>The Director of the Institute may
establish a National Alzheimer’s Coordinating Center to facilitate
collaborative research among the Alzheimer’s Disease Centers and Alzheimer’s
Disease Research Centers established under section
445.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</subsection><subsection id="IDC3FD8910B84A478F8733799A4F89D996"><enum>(b)</enum><header>Alzheimer’s
Disease Centers</header><text>Section 445(a)(1) of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–2(a)(1)) is amended by inserting <quote>, and outcome measures and disease
management</quote> after <quote>treatment methods</quote>.</text>
</subsection></section><section id="IDFEE89E61B52B4BC3B46BDF2FAB55CE7D"><enum>105.</enum><header>Research on
Alzheimer’s disease caregiving</header><text display-inline="no-display-inline">Section 445C of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–5) is amended—</text>
<paragraph id="ID026FC760797E40CB8537C7182647897E"><enum>(1)</enum><text>by striking
<quote><header-in-text>Sec. 445C.</header-in-text> (a)</quote> and inserting
the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" id="ID6D916583371448ACA1DBDB656EC9E868" reported-display-style="strikethrough" style="OLC">
<section id="ID77FC615CADF64F78B200F0AB52727D8B"><enum>445C.</enum><header>Research on
Alzheimer’s disease services and caregiving</header>
<subsection id="IDA3411E860C094820881530BC007D81BA"><enum>(a)</enum><header>Services
Research</header>
</subsection></section><after-quoted-block>;</after-quoted-block></quoted-block>
</paragraph><paragraph id="ID7F7605DAD0894B2CB56E18B13B54E48E"><enum>(2)</enum><text>by striking
subsections (b), (c), and (e);</text>
</paragraph><paragraph id="IDB667417591204C65875F1B4DE9EFEDD1"><enum>(3)</enum><text>by inserting after
subsection (a) the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" id="ID2B3ADE24F31C43FB90536A3E0E10060A" reported-display-style="strikethrough" style="OLC">
<subsection id="ID32B1A4D9F2534F5B8A2A8CFB9B3B2F1A"><enum>(b)</enum><header>Interventions
Research</header><text>The Director shall, in collaboration with the directors
of the other relevant institutes and centers of the National Institutes of
Health, conduct, or make grants for the conduct of, clinical, social, and
behavioral research related to interventions designed to help caregivers of
patients with Alzheimer’s disease and related disorders and improve patient
outcomes.</text>
</subsection><after-quoted-block>;
and</after-quoted-block></quoted-block>
</paragraph><paragraph id="ID0FB622E3E4134ECFB07339EC4BF9B9D2"><enum>(4)</enum><text>in subsection (d)
by striking <quote>(d) the Director</quote> and inserting <quote>(c)
<header-in-text>Model Curricula and Techniques</header-in-text>.—The
Director</quote>.</text>
</paragraph></section><section id="id33D914D68E5E4FE48E81A83519276B55"><enum>106.</enum><header>National summit
on alzheimer's disease</header>
<subsection id="ID2B6257020E2E4047BF7BFFE30943D8E6"><enum>(a)</enum><header>In
General</header><text>Not later than 3 years after the date of enactment of
this Act, and every 3 years thereafter, the Secretary of Health and Human
Services (referred to in this section as the <quote>Secretary</quote>) shall
convene a summit of researchers, representatives of academic institutions,
Federal and State policymakers, public health professionals, and
representatives of voluntary health agencies to provide a detailed overview of
current research activities at the National Institutes of Health, as well as to
discuss and solicit input related to potential areas of collaboration between
the National Institutes of Health and other Federal health agencies, including
the Centers for Disease Control and Prevention, the Administration on Aging,
the Agency for Healthcare Research and Quality, and the Health Resources and
Services Administration, related to research, prevention, and treatment of
Alzheimer’s disease.</text>
</subsection><subsection id="ID98830D9FFFAF49F888EEB19C746EC3AD"><enum>(b)</enum><header>Focus
Areas</header><text>The summit convened under subsection (a) shall focus
on—</text>
<paragraph id="ID20DBBA2983104F56BAFE39DE0D35E28F"><enum>(1)</enum><text>a broad range of
Alzheimer’s disease research activities relating to biomedical research,
prevention research, and caregiving issues;</text>
</paragraph><paragraph id="IDF870E5F8BB0644F08E25E9288A049049"><enum>(2)</enum><text>clinical research
for the development and evaluation of new treatments for the disease;</text>
</paragraph><paragraph id="ID1A6AE555BB5B400EBE2CE61B48E88E84"><enum>(3)</enum><text>translational
research on evidence-based and cost-effective best practices in the treatment
and prevention of the disease;</text>
</paragraph><paragraph id="ID5E15F63CA2F441E5B9F1B8B26A2855B1"><enum>(4)</enum><text>information and
education programs for health care professionals and the public relating to the
disease;</text>
</paragraph><paragraph id="ID33544ADEED0D45CDAA64A90F4BE4BB50"><enum>(5)</enum><text>priorities among
the programs and activities of the various Federal agencies regarding such
diseases; and</text>
</paragraph><paragraph id="IDE72ADBEBAAD247B98A5180E39F683C65"><enum>(6)</enum><text>challenges and
opportunities for scientists, clinicians, patients, and voluntary organizations
relating to the disease.</text>
</paragraph></subsection><subsection id="ID87376A2E1649400084E55696689D330A"><enum>(c)</enum><header>Report</header><text>Not
later than 180 days after the date on which the National Summit on Alzheimer’s
Disease is convened under subsection (a), the Director of National Institutes
of Health shall prepare and submit to the appropriate committees of Congress a
report that includes a summary of the proceedings of the summit and a
description of Alzheimer’s research, education, and other activities that are
conducted or supported through the national research institutes.</text>
</subsection><subsection id="ID0C291B2CACC04EEB8A6945E4ED6B156D"><enum>(d)</enum><header>Public
Information</header><text>The Secretary shall make readily available to the
public information about the research, education, and other activities relating
to Alzheimer’s disease and other related dementias, conducted or supported by
the National Institutes of Health.</text>
</subsection></section><enum>II</enum><header>Public health
promotion and prevention of Alzheimer's disease</header>
<section id="IDc7073913d4114e638f341389d5996679"><enum>201.</enum><header>Enhancing
public health activities related to cognitive health, Alzheimer's disease, and
other dementia's</header><text display-inline="no-display-inline">Part P of
title III of the Public Health Service Act (42 U.S.C. 280g et seq.) is amended
by adding at the end the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="idC2437E782C8F45C9A212DB1050B9C1B8" reported-display-style="strikethrough" style="OLC">
<section id="IDe4603f6888844d928f24d9de3e49a31e"><enum>399R.</enum><header>Alzheimer's
disease public education campaign</header>
<subsection id="IDc021bacfa042431fb1c9a0d345dd63c8"><enum>(a)</enum><header>In
general</header><text>The Secretary, acting through the Director of the Centers
for Disease Control and Prevention, shall directly or through grants,
cooperative agreements, or contracts to eligible entities, conduct, support,
and promote the coordination of research, investigations, demonstrations,
training, and studies relating to the control, prevention, and surveillance of
the risk factors associated with cognitive health, Alzheimer’s disease, and
other dementia’s, and seek early recognition and intervention in the course of
Alzheimer’s disease and other dementias.</text>
</subsection><subsection id="IDd17f9f69458e438cbe4274f57cc41b94"><enum>(b)</enum><header>Certain
activities</header><text>Activities under subsection (a) shall include—</text>
<paragraph id="id34915878A8BC431383C904E6AF3BEA22"><enum>(1)</enum><text>providing support
for the dissemination and implementation of the Roadmap to Maintaining
Cognitive Health to effectively mobilize the public health community into
action;</text>
</paragraph><paragraph id="ID4c3b93e5a344405883f35c0b4a99f4c0"><enum>(2)</enum><text>the development of
coordinated public education programs, services, and demonstrations which are
designed to increase general awareness of cognitive function and promote a
brain healthy lifestyle;</text>
</paragraph><paragraph id="IDb5dc898a9a7e43f980f255c9ff65a2ae"><enum>(3)</enum><text>the development of
targeted communication strategies and tools to educate health professionals and
service providers about the early recognition, diagnosis, care, and management
of Alzheimer's disease and dementia, and to provide consumers with information
about interventions, products, and services that promote cognitive health and
assist consumers in maintaining current understanding about cognitive health
based on the best science available; and</text>
</paragraph><paragraph id="ID814c3ab692b14a219db5058926f2343d"><enum>(4)</enum><text>provide support
for the collection, publication, and analysis of data on the prevalence and
incidence of cognitive health, Alzheimer's disease, and other dementias, and
the evaluation of existing population-based surveillance systems (such as the
Behavioral Risk Factors Surveillance Survey (BRFFS) and the National Health
Interview Survey (NHIS)) to identify limitations that exist in the area of
cognitive health, and if necessary, the development of a surveillance system
for cognitive decline, including Alzheimer's disease and dementia.</text>
</paragraph></subsection><subsection id="ID29488c58833f4e1cad10656834104202"><enum>(c)</enum><header>Grants</header><text>The
Secretary may award grants under this section—</text>
<paragraph id="ID900d2c1f184642b7a61371bab861010b"><enum>(1)</enum><text>to State and local
health agencies for the purpose of—</text>
<subparagraph id="ID68972a282328467e968b212b446aa9f2"><enum>(A)</enum><text>coordinating
activities related to cognitive health, Alzheimer's disease, and other
dementias with existing State-based health programs and community-based
organizations;</text>
</subparagraph><subparagraph id="IDa4301605c5494ae584247e1f3b40d488"><enum>(B)</enum><text>providing
Alzheimer's disease education and training opportunities and programs for
health professionals; and</text>
</subparagraph><subparagraph id="ID3160af102a2a4762899a95777ab11638"><enum>(C)</enum><text>developing,
testing, evaluating, and replicating effective Alzheimer's disease intervention
programs to maintain or improve cognitive health; and</text>
</subparagraph></paragraph><paragraph id="IDf46587e0ab5f4c448c4523c81ac7e371"><enum>(2)</enum><text>to nonprofit
private health organizations with expertise in providing care and services to
individuals with Alzheimer’s disease for the purpose of—</text>
<subparagraph id="ID9a0c9e8b2abb41e38e79e61bf395c6a4"><enum>(A)</enum><text>disseminating
information to the public;</text>
</subparagraph><subparagraph id="IDb27c04b57ab74f639cc0ad2a7883084f"><enum>(B)</enum><text>testing model
intervention programs to improve cognitive health; and</text>
</subparagraph><subparagraph id="IDbb1a2d1f40cd40ac85f556ddeaa4db67"><enum>(C)</enum><text>coordinating
existing services with State-based health programs.</text>
</subparagraph></paragraph></subsection><subsection id="IDbe4790d208d443169360b237028a620d"><enum>(d)</enum><header>Authorization of
appropriations</header><text>For the purpose of carrying out this section,
there are authorized to be appropriated $15,000,000 for fiscal year 2008, and
such sums as may be necessary for each of fiscal years 2009 through
2012.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>III</enum><header>Assistance for
caregivers</header>
<section id="id3F31E4CFB9514285AD49E8C0DD23E3CF"><enum>301.</enum><header>Alzheimer's
disease call center</header><text display-inline="no-display-inline">Part P of
title III of the Public Health Service Act (42 U.S.C. 280g et seq.), as amended
by section 201, is further amended by adding at the end the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="id5AF21941F3324082A0D56AAE35972ED1" reported-display-style="strikethrough" style="OLC">
<section id="idF6B4237BE2BF4C889533E060C1BC725E"><enum>399S.</enum><header>Alzheimer's
disease call center</header>
<subsection id="ID5702620ebeb44aeeaebf139a5301291e"><enum>(a)</enum><header>In
general</header><text>The Secretary, acting through the Administration on
Aging, shall award a cooperative grant to a non-profit or community-based
organization to support the establishment and operation of an Alzheimer’s Call
Center that is accessible 24 hours a day, 7 days a week, to provide expert
advice, care consultation, information, and referrals nationwide at the
national and local level regarding Alzheimer's disease.</text>
</subsection><subsection id="ID09255a125b914c86a33ec915cb50c94c"><enum>(b)</enum><header>Activities</header><text>The
Alzheimer’s Call Center established under subsection (a) shall—</text>
<paragraph id="id0DC2477ACCB7450E8BAA9D2BCFA8CDAF"><enum>(1)</enum><text>collaborate with
the Administration on Aging in the development, modification, and execution of
the Call Center’s work plan;</text>
</paragraph><paragraph id="idF548EB568EDF42EBB5D01EA7292D901A"><enum>(2)</enum><text>assist the
Administration on Aging in developing and sustaining collaborations between the
Alzheimer’s Call Center, the Eldercare Locator, the grantees under the
Alzheimer’s Demonstration Program, and the Aging Network;</text>
</paragraph><paragraph id="idCFF8BCFEC1A54C478F4D2F7B564D4F04"><enum>(3)</enum><text>provide a 24-hour
a day, 7-days a week toll-free Call Center with trained professional staff who
are available to provide care consultation and crisis intervention to
individuals with Alzheimer’s disease and other dementias, their family and
informal caregivers, and others as appropriate;</text>
</paragraph><paragraph id="idD35B7E93863B4DA69645C458EAAE8636"><enum>(4)</enum><text>be accessible by
telephone through a single 1–800 telephone number, website and e-mail address;
and</text>
</paragraph><paragraph id="id5B338D4B40C04BB4ACDC0D52E07A4F46"><enum>(5)</enum><text>evaluate the
impact of the Call Center’s activities and services.</text>
</paragraph></subsection><subsection id="IDfffb5b9b772c4caaaad5e95b7a72c687"><enum>(c)</enum><header>Multilingual
capacity</header><text>The Call Center established under this section shall
have a multilingual capacity and shall respond to inquiries in at least 140
languages through its own bilingual staff and with the use of a language
translation service.</text>
</subsection><subsection id="IDccf73a61f8324af7966f01c97377b897"><enum>(d)</enum><header>Response to
emergency and ongoing needs</header><text>The Call Center established under
this section shall collaborate with community-based organizations, including
non-profit agencies and organizations, to ensure local, on-the-ground capacity
to respond to emergency and on-going needs of Alzheimer’s patients, their
families, and informal caregivers.</text>
</subsection><subsection id="IDac6301b4813045ebb0381c81d277e333"><enum>(e)</enum><header>Authorization of
appropriations</header><text>For the purpose of carrying out this section,
there are authorized to be appropriated $1,000,000 for fiscal year 2008, and
such sums as may be necessary for each of fiscal years 2009 through
2012.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><section id="IDe46feb50167b4736976e2e7390c8e1cd"><enum>302.</enum><header>Innovative
Alzheimer's care State matching grant program</header>
<subsection id="id3765EDDA17304A4C9AB22DCA29C52A9E"><enum>(a)</enum><header>Authorization of
appropriations</header><text display-inline="yes-display-inline">Section
398B(e) of the Public Health Service Act (42 U.S.C. 280c–5(e)) is
amended—</text>
<paragraph id="id24E513FCED394007995DBD8409DAE36C"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>and such</quote> and
inserting <quote>such</quote>; and</text>
</paragraph><paragraph id="idA28DB3EE39474ABBB0D8B5B25ADAC855"><enum>(2)</enum><text display-inline="yes-display-inline">by inserting before the period the
following: <quote>, $25,000,000 for fiscal year 2008, and such sums as may be
necessary for each of fiscal years 2009 through 2012</quote>.</text>
</paragraph></subsection><subsection id="IDeee3d89bfd764c6f9746b65ed7d79fba"><enum>(b)</enum><header>Program
expansion</header><text>Section 398(a) of the Public Health Service Act (42
U.S.C. 280c–3(a))</text>
<paragraph id="ID99e0f14b7f1142c58f120bc19a849c48"><enum>(1)</enum><text>in paragraph (2),
by inserting after <quote>other respite care</quote> the following: <quote>and
care consultation including assessment of needs, assistance with planning and
problem solving and providing supportive listening</quote>;</text>
</paragraph><paragraph id="IDfb86ed32a2e7412a97e07dbe66230e34"><enum>(2)</enum><text>in paragraph (3),
by striking <quote>; and</quote> and inserting the following: <quote>and
individuals in frontier areas (as defined as areas with 6 or fewer people per
square mile or areas in which it takes people at least 60 minutes or 60 miles
to reach a market or service area);</quote>;</text>
</paragraph><paragraph id="id6FF9E03A5E984C07BF888B0F04996710"><enum>(3)</enum><text>in paragraph (4),
by striking the period at the end and inserting a semicolon; and</text>
</paragraph><paragraph id="ID807665fa5fb446659ed2434e85667f9b"><enum>(4)</enum><text>by adding at the
end the following:</text>
<quoted-block changed="deleted" committee-id="SSHR00" display-inline="no-display-inline" id="id5D3B01207D114EAFAF20B1FF05B464E0" reported-display-style="strikethrough" style="OLC">
<paragraph id="ID24815584c0e3400b9c87bded3e228ce4"><enum>(5)</enum><text>to encourage
grantees under this section to coordinate activities with other State officials
administering efforts to promote long-term care options that enable older
individuals to receive long-term care in home- and community-based settings, in
a manner responsive to the needs and preferences of older individuals and their
family caregivers;</text>
</paragraph><paragraph id="IDfde98bb448c7453cb131579e8833f429"><enum>(6)</enum><text>to encourage
grantees under this section to—</text>
<subparagraph id="id50C06107104E49349BA7950B5849A1E7"><enum>(A)</enum><text>engage in
activities that support early detection and diagnosis of Alzheimer’s disease
and related dementia;</text>
</subparagraph><subparagraph id="idFDA96FCDDD8A4A2B8549A7D353AD917F"><enum>(B)</enum><text>provide training
to medical personnel including hospital staff, emergency room personnel, home
health care workers and physician office staff, rehabilitation services
providers, and caregivers about how Alzheimer’s can affect behavior and impede
communication in medical and community settings;</text>
</subparagraph><subparagraph id="id40D8D478926F48BA8C5E615B23CF720A"><enum>(C)</enum><text>develop guidelines
to provide the medical community with up-to-date information about the best
methods of care for individuals with Alzheimer’s disease;</text>
</subparagraph><subparagraph id="id0718612A10124C42ABB5EF97578919F2"><enum>(D)</enum><text>inform community
physicians about available resources to assist them in detecting and managing
Alzheimer’s; and</text>
</subparagraph><subparagraph id="idE5813A4BD18240F8B6FE5856A6D1C6E3"><enum>(E)</enum><text>raise awareness
among community physicians about the availability of community-based
organizations which can assist individuals with Alzheimer’s and their
caregivers;</text>
</subparagraph></paragraph><paragraph id="id7DF884E3A90B47C1BF8415D5334BC88F"><enum>(7)</enum><text>to encourage
grantees under this section to engage in activities that use findings from
evidence-based research on service models and techniques to support individuals
with Alzheimer’s disease and their caregivers; and</text>
</paragraph><paragraph id="IDfdd19409bf3d42ed8f1545eb35a227c1"><enum>(8)</enum><text>to encourage
grantees under this section to incorporate best practices for effectively
serving individuals with Alzheimer’s disease in community-based settings into
ongoing State systems change and long-term care
activities.</text>
</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
</paragraph></subsection></section>
1.This Act may be cited as the
Alzheimer’s Breakthrough Act of
2007
.
2.Congress makes the following
findings:
(1)Alzheimer's disease is a
disorder that destroys cells in the brain. The disease is the leading cause of
dementia, a condition that involves gradual memory loss, decline in the ability
to perform routine tasks, disorientation, difficulty in learning, loss of
language skills, impairment of judgment, and personality changes. As the
disease progresses, people with Alzheimer's disease become unable to care for
themselves. The loss of brain cells eventually leads to the failure of other
systems in the body.
(2)An estimated 4,500,000
Americans have Alzheimer's disease and 1 in 10 individuals have a family member
with the disease. By 2050, the number of individuals with the disease could
range from 13,000,000 to 16,000,000 unless science finds a way to prevent or
cure the disease.
(3)One in 10 people over the
age of 65, and nearly half of those over the age of 85 have Alzheimer's
disease. Younger people also get the disease.
(4)The Alzheimer's disease
process may begin in the brain as many as 20 years before the symptoms of
Alzheimer's disease appear. An individual will live an average of 8 years and
as many as 20 once the symptoms of Alzheimer's disease appear.
(5)The average lifetime cost
of care for an individual with Alzheimer's disease is $170,000.
(6)In 2005, Medicare alone
spent $91,000,000,000 for the care of individuals with Alzheimer's disease and
this amount is projected to increase to $160,000,000,000 in 2010.
(7)Ninety-five percent of
Medicare beneficiaries with Alzheimer’s disease have one or more other chronic
conditions that are common in the elderly, coronary heart disease (30 percent),
congestive heart failure (28 percent), diabetes (21 percent), and chronic
obstructive pulmonary disease (17 percent).
(8)Seven in 10 individuals
with Alzheimer's disease live at home. While almost 75 percent of home care is
provided by family and friends, the average annual cost of paid care for people
with Alzheimer's disease at home is $19,000 per year. Almost all families pay
this cost out of pocket.
(9)Half of all nursing home
residents have Alzheimer's disease or a related disorder. The average annual
cost of Alzheimer's disease nursing home care is more than $70,000. Medicaid
pays half of the total nursing home bill and helps 2 out of 3 residents pay for
their care. Medicaid expenditures for nursing home care for people with
Alzheimer's disease are estimated to increase from $21,000,000,000 in 2005 to
$24,000,000,000 in 2010.
(10)In fiscal year 2007, the
Federal Government will spend an estimated $642,000,000 on Alzheimer's disease
research. If the United States achieves its research goals (preventing the
onset of Alzheimer's disease in those at risk and treating and delaying
progression of the disease in those who have symptoms), annual Medicare savings
would be $51,000,000,000 by 2015 and $88,000,000,000 by 2020. Annual Medicaid
savings would be $10,000,000,000 in 2015 and $17,000,000,000 by 2020 and the
projected number of cases of Alzheimer's disease would be reduced by 40 percent
by the middle of the century.
(11)An analysis by the
Montefiore Medical Center and the Albert Einstein College of Medicine estimated
that the annual value of the informal care system is $306,000,000,000. Family
caregiving comes at enormous physical, emotional, and financial sacrifice,
putting the whole system at risk.
(12)One in 8 Alzheimer's
disease caregivers becomes ill or injured as a direct result of caregiving. One
in 3 uses medication for problems related to caregiving. Older caregivers are 3
times more likely to become clinically depressed than others in their age
group.
(13)Elderly spouses strained
by caregiving are 63 percent more likely to die during a given 4-year period
than other spouses their age.
(14)Almost 3 of 4 caregivers
are women. One in 3 has children or grandchildren under the age of 18 living at
home. Caregiving leaves them less time for other family members and they are
much more likely to report family conflicts because of their caregiving
role.
(15)Most Alzheimer's disease
caregivers work outside the home before beginning their caregiving careers, but
caregiving forces them to miss work, cut back to part-time, take less demanding
jobs, choose early retirement, or give up work altogether. As a result, in
2002, Alzheimer's disease cost American business an estimated $36,500,000,000
in lost productivity, as well as an additional $24,600,000,000 in business
contributions to the total cost of care.
<enum>I</enum><header>Increasing the Federal
commitment to alzheimer’s research</header>
<section id="idbe6c1230-a8c6-4b8e-b591-14b809559bdf"><enum>101.</enum><header>Increase in nih
funding for Alzheimer’s disease research</header><text display-inline="no-display-inline">For the purpose of conducting and supporting
research on Alzheimer’s disease, cognitive health, and related disorders
(including related activities under subpart 5 of part C of title IV of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e et seq.) there is authorized to be appropriated $780,000,000 for fiscal
year 2008, $910,000,000 for fiscal year 2009, $1,040,000,000 for fiscal year
2010, $1,170,000,000 for fiscal year 2011, and $1,300,000,000 for fiscal year
2012.</text>
</section><section id="idb57ca0a2-a3fc-41f9-9be1-92a5391d2603"><enum>102.</enum><header>Priority to
Alzheimer’s disease research</header><text display-inline="no-display-inline">Section 444(d) of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–1(d)) is amended by adding at the end the following: <quote>The Director
of the Institute shall continue to make research related to Alzheimer’s
Disease, cognitive health, and related disorders’, a priority within the
Institute’s activities consistent with the peer-review process.</quote>.</text>
</section><section id="id0de2185e-cfe0-41fd-be5c-2d46e615bfaa"><enum>103.</enum><header>Alzheimer's disease
prevention initiative</header><text display-inline="no-display-inline">Section
444 of the <act-name parsable-cite="PHSA">Public Health Service Act</act-name>
(42 U.S.C. 285e–1), as amended by section 102, is further amended by adding at
the end the following:</text>
<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="idb3044980-afda-4f7b-8b24-0e1c3387a72f" reported-display-style="italic" style="OLC">
<subsection id="iddac868f1-e9f0-4863-b5f3-515e32d21bff"><enum>(e)</enum><header>Prevention
trials</header><text>The Director of the Institute, shall increase the emphasis
on the need to conduct Alzheimer's disease, cognitive health, and related
disorders prevention trials within the National Institutes of Health.</text>
</subsection><subsection id="idb02506c8-bab0-484c-a3ed-e13f07932e7b"><enum>(f)</enum><header>Neuroscience
initiative</header><text>The Director of the Institute, shall ensure that
Alzheimer’s disease, cognitive health, and related disorders is maintained as a
high priority for the existing neuroscience
initiative.</text>
</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
</section><section id="id059cdb49-6a81-46a0-9f02-22adc2e2dc53"><enum>104.</enum><header>Alzheimer’s disease
clinical research</header>
<subsection id="id46d553b7-3630-40c1-928d-6b995c83d42d"><enum>(a)</enum><header>Clinical
Research</header><text>Subpart 5 of part C of title IV of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e et seq.) is amended by adding at the end the following:</text>
<quoted-block act-name="Public Health Service Act" changed="added" committee-id="SSHR00" id="id3402e481-e9ba-434b-81b4-9ab26a8cd279" reported-display-style="italic" style="OLC">
<section id="id968dca0a-73a3-421a-ab89-ed824b8843c4"><enum>445J.</enum><header>Alzheimer’s disease
clinical research</header>
<subsection id="id647933a7-fd4c-4360-93b1-b4f35ea3136b"><enum>(a)</enum><header>In
General</header><text>The Secretary, acting through the Director of the
Institute, pursuant to subsection (d) of section 444, shall, consistent with
the peer-review and priority setting process of the Institute, conduct and
support cooperative clinical research regarding Alzheimer’s disease, cognitive
health, and related disorders. Such research may include—</text>
<paragraph id="id8625084c-e280-48bb-9a4c-9ce59517e149"><enum>(1)</enum><text>investigating therapies,
interventions, and agents to detect, treat, slow the progression of, or prevent
Alzheimer’s disease;</text>
</paragraph><paragraph id="id6964709d-0a76-41b6-bb07-8b55d011a029"><enum>(2)</enum><text>enhancing the national
infrastructure for the conduct of clinical trials;</text>
</paragraph><paragraph id="id28666280-e02f-45ec-b9ea-17718a10790e"><enum>(3)</enum><text>developing and testing
novel approaches to the design and analysis of such trials;</text>
</paragraph><paragraph id="idbc5123f3-b744-48bc-9622-a5fa95d57ff8"><enum>(4)</enum><text>facilitating the
enrollment of patients for such trials, including patients from diverse
populations;</text>
</paragraph><paragraph id="id0e4367c5-e772-4c9e-a708-be4a065cdec7"><enum>(5)</enum><text>developing improved
diagnostics and means of patient assessment for Alzheimer’s disease;</text>
</paragraph><paragraph id="idb43737ce-f1b6-4548-adde-9edfb0f1e047"><enum>(6)</enum><text>the conduct of clinical
trials on potential therapies, including readily available compounds such as
herbal remedies and other alternative treatments;</text>
</paragraph><paragraph id="idcc0b1377-ef37-4439-95a9-2389e429d827"><enum>(7)</enum><text>research to develop
better methods of early diagnosis, including the use of current imaging
techniques;</text>
</paragraph><paragraph id="idD40FDBAC6D5B4F9A8B8DF3475634197B"><enum>(8)</enum><text>enhance research
currently being done on minorities and health disparities; and</text>
</paragraph><paragraph id="idca795f56-efd3-4b8b-9e7e-6d86eb6e6a0f"><enum>(9)</enum><text>other research as
determined appropriate by the Director of the Institute, the Alzheimer’s
Disease Centers and Alzheimer’s Disease Research Centers established under
section 445.</text>
</paragraph></subsection><subsection id="id3db48fa1-ccdc-488b-8979-b89fbefc6973"><enum>(b)</enum><header>Early Diagnosis and
Detection Research</header>
<paragraph id="id3fa80ded-cacd-4150-b111-a06e918441c6"><enum>(1)</enum><header>In
general</header><text>The Secretary, acting through the Director of the
Institute, in consultation with the directors of other relevant institutes and
centers of the National Institutes of Health, shall conduct, or make grants for
the conduct of, research related to the early detection, diagnosis, and
prevention of Alzheimer’s disease and of mild cognitive impairment or other
potential precursors to Alzheimer’s disease.</text>
</paragraph><paragraph id="id5f28c7b7-afd6-495f-a7b4-ca2b0ca925f7"><enum>(2)</enum><header>Evaluation</header><text>The
research described in paragraph (1) may include the evaluation of diagnostic
tests and imaging techniques.</text>
</paragraph><paragraph id="ID34c7c43f18434570b23cada2f4199aa4"><enum>(3)</enum><header>Study on the prevalence
and causes of early onset dementia</header><text>The Director of the Institute
is encouraged to explore the feasibility and scientific opportunities in
research regarding the prevalence and causes of early onset dementia (diagnosed
before the age of 65).</text>
</paragraph></subsection><subsection id="id690cff24-5abb-44b5-abea-7d2db8369baa"><enum>(c)</enum><header>Vascular
Disease</header><text>The Secretary, acting through the Director of the
Institute, in consultation with the directors of other relevant institutes and
centers of the National Institutes of Health, are strongly encouraged to
conduct or make grants for the conduct of research related to the relationship
of vascular disease and Alzheimer’s disease and related disorders, including
clinical trials to determine whether drugs developed to prevent cerebrovascular
disease can prevent the onset or progression of Alzheimer’s disease.</text>
</subsection><subsection id="id6a575d15-0869-46c6-ab83-3c2104ea0555"><enum>(d)</enum><header>Treatments and
prevention</header><text>The Secretary, acting through the Director of the
Institute, shall place special emphasis on expediting the translation of
research findings under this section into effective treatments and prevention
strategies for at-risk individuals.</text>
</subsection><subsection id="id501fce32-eb1f-40a8-ba86-33f1333b03fe"><enum>(e)</enum><header>National Alzheimer’s
Coordinating Center</header><text>The Secretary, acting through the Director of
the Institute, may establish a National Alzheimer’s Coordinating Center to
facilitate collaborative research among the Alzheimer’s Disease Centers and
Alzheimer’s Disease Research Centers established under section
445.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</subsection><subsection id="id4700b151-b951-4d74-91dd-4994384eb36b"><enum>(b)</enum><header>Alzheimer’s Disease
Centers</header><text>Section 445(a)(1) of the <act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–2(a)(1)) is amended by inserting <quote>, and outcome measures and disease
management</quote> after <quote>treatment methods</quote>.</text>
</subsection></section><section id="ide097313d-7766-4001-83f5-eb692fcddcf0"><enum>105.</enum><header>Research on
Alzheimer’s disease caregiving</header><text display-inline="no-display-inline">Section 445C of the
<act-name parsable-cite="PHSA">Public Health Service Act</act-name> (42 U.S.C.
285e–5) is amended—</text>
<paragraph id="ideeec4125-0a7b-497e-9ef2-fd4c6dbc1222"><enum>(1)</enum><text>by striking
<quote><header-in-text>Sec. 445C.</header-in-text> (a)</quote> and inserting
the following:</text>
<quoted-block changed="added" committee-id="SSHR00" id="id3f2ec6c2-cbad-4e78-b362-829299d7b6d4" reported-display-style="italic" style="OLC">
<section id="id3b2c252f-1ab0-402b-834a-ae26de3eefea"><enum>445C.</enum><header>Research on
Alzheimer’s disease services and caregiving</header>
<subsection id="id9ee8085d-c76a-4c2d-b811-a0aef74be07b"><enum>(a)</enum><header>Services
Research</header>
</subsection></section><after-quoted-block>;</after-quoted-block></quoted-block>
</paragraph><paragraph id="id4bf9374d-e571-4710-8b5d-0b430b02cee5"><enum>(2)</enum><text>by striking subsections
(b), (c), and (e);</text>
</paragraph><paragraph id="id5e1d0a5f-b0f1-47b1-a90a-d47e6a4b0464"><enum>(3)</enum><text>by inserting after
subsection (a) the following:</text>
<quoted-block changed="added" committee-id="SSHR00" id="id599a9c74-651e-4801-bc20-2bdff0d2baf1" reported-display-style="italic" style="OLC">
<subsection id="id3ca2dd94-4e60-4d3a-b897-e9055caa6b31"><enum>(b)</enum><header>Interventions
Research</header><text>The Secretary, acting through the Director, shall, in
collaboration with the directors of the other relevant institutes and centers
of the National Institutes of Health, conduct, or make grants for the conduct
of, clinical, social, and behavioral research related to interventions designed
to help caregivers of patients with Alzheimer’s disease and related disorders
and improve patient outcomes.</text>
</subsection><after-quoted-block>;
and</after-quoted-block></quoted-block>
</paragraph><paragraph id="id5f960b5a-f5ae-44d1-832d-57eb0ee2d00a"><enum>(4)</enum><text>in subsection (d) by
striking <quote>(d) the Director</quote> and inserting <quote>(c)
<header-in-text level="subsection" style="OLC">Model Curricula and
Techniques</header-in-text>.—The Director</quote>.</text>
</paragraph></section><section id="idb539e3bf-560c-4584-a973-435db5adfbb8"><enum>106.</enum><header>National summit on
Alzheimer's disease and related disorders</header>
<subsection id="idea2e975b-a22e-4915-b47e-95a42af85e1d"><enum>(a)</enum><header>In
General</header><text>Not later than 3 years after the date of enactment of
this Act, and every 3 years thereafter, the Secretary of Health and Human
Services (referred to in this section as the <quote>Secretary</quote>) shall
convene a summit of researchers, representatives of academic institutions,
Federal and State policy makers, public health professionals, community health
organizations, and representatives of voluntary health organizations to provide
a detailed overview of current research activities at the National Institutes
of Health, as well as to discuss and solicit input related to potential areas
of collaboration between the National Institutes of Health and other Federal
health agencies, including the Centers for Disease Control and Prevention, the
Administration on Aging, the Agency for Healthcare Research and Quality, and
the Health Resources and Services Administration, related to research,
prevention, and treatment of Alzheimer’s disease.</text>
</subsection><subsection id="id1f97f593-c8bb-4656-9a2d-ff6c388e39fe"><enum>(b)</enum><header>Focus
Areas</header><text>The summit convened under subsection (a) shall focus
on—</text>
<paragraph id="ide7a21fd6-4d27-4e3a-a113-ff13c047d45b"><enum>(1)</enum><text>a broad range of
Alzheimer’s disease research activities relating to breakthroughs in biomedical
research, prevention research, and caregiving issues;</text>
</paragraph><paragraph id="idc06bfec2-08d2-4d3c-9d2e-57d13e69c71c"><enum>(2)</enum><text>clinical research for the
development and evaluation of new treatments for Alzheimer's disease;</text>
</paragraph><paragraph id="ida8bddef5-d49c-4c79-adc0-6d201d3d96a5"><enum>(3)</enum><text>translational research on
evidence-based and cost-effective best practices in the treatment and
prevention of Alzheimer's disease;</text>
</paragraph><paragraph id="IDe7f3bf3646564235bbb55c3b1a278112"><enum>(4)</enum><text>international research
and activities relating to breakthroughs in prevention, diagnosis, and
treatment of Alzheimer’s disease;</text>
</paragraph><paragraph id="IDc39c4c5dd7c94952825b277217b1f01b"><enum>(5)</enum><text>advances in complimentary
and alternative medicine related to Alzheimer’s disease;</text>
</paragraph><paragraph id="id5f076c01-3707-4b87-a361-6c87f94cc7c9"><enum>(6)</enum><text>information and education
programs for health care professionals and the public relating to Alzheimer's
disease;</text>
</paragraph><paragraph id="idd6cb9b93-c69c-43a5-be0c-c7d9b296703a"><enum>(7)</enum><text>priorities among the
programs and activities of the various Federal agencies related to Alzheimer's
disease; and</text>
</paragraph><paragraph id="id1bd23703-bbbc-4e2c-811f-15f6a8ec08c7"><enum>(8)</enum><text>challenges and
opportunities for scientists, clinicians, patients, and voluntary organizations
relating to Alzheimer's disease.</text>
</paragraph></subsection><subsection id="id19b7cc15-b4d2-4c38-b92f-1ae0996b8f89"><enum>(c)</enum><header>Report</header><text>Not
later than 180 days after the date on which the National Summit on Alzheimer’s
Disease is convened under subsection (a), the Secretary, acting through the
Director of National Institutes of Health, shall prepare and submit to the
appropriate committees of Congress a report that includes a summary of the
proceedings of the summit and a description of Alzheimer’s research, education,
and other activities that are conducted or supported through the national
research institutes.</text>
</subsection><subsection id="id23898093-3fc3-4378-9b9b-ccfa0bcf3a24"><enum>(d)</enum><header>Public
Information</header><text>The Secretary shall make readily available to the
public information about the research, education, and other activities relating
to Alzheimer’s disease and other related dementias, conducted or supported by
the National Institutes of Health.</text>
</subsection></section><enum>II</enum><header>Enhanced public health
activities related to cognitive health, Alzheimer's disease and other
dementias</header>
<section id="id4a81acd4-f708-4091-95c2-2dbc69414868"><enum>201.</enum><header>Enhanced public health
activities related to cognitive health, Alzheimer's disease, and other
dementias</header><text display-inline="no-display-inline">Part P of title III
of the Public Health Service Act (42 U.S.C. 280g et seq.) is amended by adding
at the end the following:</text>
<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id57e94175-22ad-4f3f-a189-51ba9c6fa49a" reported-display-style="italic" style="OLC">
<section id="id30122135-db90-448c-a1a4-437f97e6b966"><enum>399R.</enum><header>Alzheimer's disease
public education awareness program</header>
<subsection id="id23825cef-085f-4db3-a528-79cd7d4f3811"><enum>(a)</enum><header>In
general</header><text>The Secretary, acting through the Director of the Centers
for Disease Control and Prevention, shall directly or through grants,
cooperative agreements, or contracts to eligible entities, conduct, support,
and promote the coordination of research, investigations, demonstrations,
training, and studies relating to the control, prevention, and surveillance of
the risk factors associated with cognitive health, Alzheimer’s disease, and
related disorders, and seek early recognition and intervention in the course of
Alzheimer’s disease and related disorders.</text>
</subsection><subsection id="id340ce489-a756-4081-b525-3a695da354a1"><enum>(b)</enum><header>Certain
activities</header><text>Activities under subsection (a) may include—</text>
<paragraph id="id72556c9f-35d6-4a76-843b-3ca2b90f4936"><enum>(1)</enum><text>providing support for the
dissemination and implementation of the Roadmap to Maintaining Cognitive Health
to effectively mobilize the public health community into action;</text>
</paragraph><paragraph id="id1f008f03-5f03-4d0d-afbd-7b73b658d9b4"><enum>(2)</enum><text>the development of
coordinated public education programs, services, and demonstrations which are
designed to increase general awareness of cognitive function and promote a
brain healthy lifestyle;</text>
</paragraph><paragraph id="id2f606d63-fcca-466f-abd3-6a5ba882835b"><enum>(3)</enum><text>the development of
targeted communication strategies and tools to educate health professionals and
service providers about the early recognition, diagnosis, care, and management
of Alzheimer's disease and related disorders, and to provide consumers with
information about interventions, products, and services that promote cognitive
health and assist consumers in maintaining current understanding about
cognitive health based on the best science available; and</text>
</paragraph><paragraph id="id5861992b-bf90-460e-9ac8-26859bde9ca0"><enum>(4)</enum><text>provide support for the
collection, publication, and analysis of data on the prevalence and incidence
of cognitive function, Alzheimer's disease and related disorders, and the
related public health burden, and the evaluation of existing population-based
surveillance systems (such as the Behavioral Risk Factors Surveillance Survey
(BRFFS) and the National Health Interview Survey (NHIS)) to identify
limitations that exist in the area of cognitive health, and if necessary, the
development of a surveillance system for cognitive decline, including
Alzheimer's disease and related disorders.</text>
</paragraph></subsection><subsection id="id9589e77d-116d-4382-8257-f29cc1f95b3f"><enum>(c)</enum><header>Grants</header><text>The
Secretary may award grants under this section—</text>
<paragraph id="ID299afd6cf745458a954d649180ef36e6"><enum>(1)</enum><text>to State and local health
agencies and health organizations for the purpose of—</text>
<subparagraph id="id0780e974-0c95-4f3c-96b5-3cb3bb977ad8"><enum>(A)</enum><text>coordinating activities
related to Alzheimer's disease, cognitive health, and related disorders with
existing State-based health programs and community-based organizations;</text>
</subparagraph><subparagraph id="id40d676f4-2632-41e8-a7a9-96113217eece"><enum>(B)</enum><text>providing Alzheimer's
disease, cognitive health, and related disorders education and training
opportunities and programs for health professionals; and</text>
</subparagraph><subparagraph id="ide45e82ee-fdb0-49a0-ae63-3126784408e2"><enum>(C)</enum><text>developing, testing,
evaluating, and replicating effective Alzheimer's disease and related disorders
intervention programs to maintain or improve cognitive health; and</text>
</subparagraph></paragraph><paragraph id="idc5310fbd-3dfc-4270-89ab-ae68963053fa"><enum>(2)</enum><text>to nonprofit private
health organizations with expertise in providing care and services to
individuals with Alzheimer’s disease and related disorders for the purpose
of—</text>
<subparagraph id="id590e63f4-0f85-4875-b7dc-667358073956"><enum>(A)</enum><text>disseminating information
to the public;</text>
</subparagraph><subparagraph id="idf72728ff-8f90-4597-a82e-fae0c221d892"><enum>(B)</enum><text>testing model
intervention programs to improve cognitive health; and</text>
</subparagraph><subparagraph id="id93979a0f-ffb0-4c3e-9020-f9459e043601"><enum>(C)</enum><text>coordinating existing
services with State-based health programs.</text>
</subparagraph></paragraph></subsection><subsection id="ID71c203c23f9c4c7a876f295c80ba4a53"><enum>(d)</enum><header>Authorization of
appropriations</header><text>For the purpose of carrying out this section,
there are authorized to be appropriated $3,000,000 for each of fiscal years
2008 through
2012.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><enum>III</enum><header>Assistance for
caregivers</header>
<section id="ide705502b-63bd-4c68-8894-9adde4024931"><enum>301.</enum><header>Alzheimer's disease
call center</header><text display-inline="no-display-inline">Part P of title
III of the Public Health Service Act (42 U.S.C. 280g et seq.), as amended by
section 201, is further amended by adding at the end the following:</text>
<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="id493638b0-faa7-4c85-88ac-790e722cc85d" reported-display-style="italic" style="OLC">
<section id="idce43ba29-bc6b-4c01-b0f4-42ee7f2dfaea"><enum>399S.</enum><header>Alzheimer's disease
call center</header>
<subsection id="id824db356-ef04-4979-bcfe-0e599e9dbe6a"><enum>(a)</enum><header>In
general</header><text>The Secretary, acting through the Administration on
Aging, shall award a cooperative grant to a non-profit or community-based
organization to support the establishment and operation of an Alzheimer’s Call
Center that is accessible 24 hours a day, 7 days a week, to provide expert
advice, care consultation, information, and referrals nationwide at the
national and local level regarding Alzheimer's disease and related
disorders.</text>
</subsection><subsection id="idebbdb3e2-914d-4110-acd0-91e628d8ae3e"><enum>(b)</enum><header>Activities</header><text>The
Alzheimer’s Call Center established under subsection (a) shall—</text>
<paragraph id="id3667df43-118c-4d09-8d6e-71a0e75815c3"><enum>(1)</enum><text>collaborate with the
Administration on Aging in the development, modification, and execution of the
Call Center’s work plan;</text>
</paragraph><paragraph id="id0d96341a-bf55-411a-ac46-76d041e695db"><enum>(2)</enum><text>assist the Administration
on Aging in developing and sustaining collaborations between the Alzheimer’s
Call Center, the Eldercare Locator, the grantees under the Alzheimer’s
Demonstration Program, and the Aging Network;</text>
</paragraph><paragraph id="idb89fc6bd-c225-40f4-ad18-b38b9b33773f"><enum>(3)</enum><text>provide a 24-hour a day,
7-days a week toll-free Call Center with trained professional staff who are
available to provide care consultation and crisis intervention to individuals
with Alzheimer’s disease and other dementias, their family and informal
caregivers, and others as appropriate;</text>
</paragraph><paragraph id="id161cc67a-5ca2-435d-8ee7-7129cecf3dc4"><enum>(4)</enum><text>be accessible by
telephone through a single 1–800 telephone number, website and e-mail address;
and</text>
</paragraph><paragraph id="id45817955-e634-4bd4-85b8-a2b9e1cfa6a1"><enum>(5)</enum><text>evaluate the impact of
the Call Center’s activities and services.</text>
</paragraph></subsection><subsection id="idfb6207b0-48f3-4557-9b31-ccd0acb9f028"><enum>(c)</enum><header>Multilingual
capacity</header><text>The Call Center established under this section shall
have a multilingual capacity and shall respond to inquiries in at least 140
languages through its own bilingual staff and with the use of a language
translation service.</text>
</subsection><subsection id="ida6b647b6-e2ef-4351-95ce-4180fba4f1bb"><enum>(d)</enum><header>Response to emergency
and ongoing needs</header><text>The Call Center established under this section
shall collaborate with community-based organizations, including non-profit
agencies and organizations, to ensure local, on-the-ground capacity to respond
to emergency and on-going needs of Alzheimer’s patients, their families, and
informal caregivers.</text>
</subsection><subsection id="id6e23b603-891b-47fc-ae3a-71699fae1931"><enum>(e)</enum><header>Authorization of
appropriations</header><text>For the purpose of carrying out this section,
there are authorized to be appropriated $1,000,000 for fiscal year 2008, and
such sums as may be necessary for each of fiscal years 2009 through
2012.</text>
</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
</section><section id="id81995126-3ffc-4fb2-815a-628cb2d886ab"><enum>302.</enum><header>Innovative Alzheimer's
care State matching grant program</header>
<subsection id="idbe490261-d394-4ac0-a13e-e171d6fc8424"><enum>(a)</enum><header>Authorization of
appropriations</header><text display-inline="yes-display-inline">Section
398B(e) of the Public Health Service Act (42 U.S.C. 280c–5(e)) is
amended—</text>
<paragraph id="id1710f1bd-dcea-4057-bf96-5e65f9ee2c24"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>and such</quote> and
inserting <quote>such</quote>; and</text>
</paragraph><paragraph id="id292774ea-36af-425c-81cb-a63a476141a5"><enum>(2)</enum><text display-inline="yes-display-inline">by inserting before the period the
following: <quote>, and $20,000,000 for each of fiscal years 2008 through
2012</quote>.</text>
</paragraph></subsection><subsection id="id1c59ecc0-cb9c-4ba7-bdf1-1a2f9bbb9434"><enum>(b)</enum><header>Program
expansion</header><text>Section 398(a) of the Public Health Service Act (42
U.S.C. 280c–3(a))</text>
<paragraph id="idbd2c5d04-a2c4-4ed5-ae04-e125687881cb"><enum>(1)</enum><text>in paragraph (2), by
inserting after <quote>other respite care</quote> the following: <quote>and
care consultation including assessment of needs, assistance with planning and
problem solving and providing supportive listening</quote>;</text>
</paragraph><paragraph id="id399ab952-8a39-46c9-83d3-f9ae223872ed"><enum>(2)</enum><text>in paragraph (3), by
striking <quote>; and</quote> and inserting the following: <quote>and
individuals in frontier areas (as defined as areas with 6 or fewer people per
square mile or areas in which it takes people at least 60 minutes or 60 miles
to reach a market or service area);</quote>;</text>
</paragraph><paragraph id="id14d3aa66-922b-44ee-a30e-670bae74a71d"><enum>(3)</enum><text>in paragraph (4), by
striking the period at the end and inserting a semicolon; and</text>
</paragraph><paragraph id="id23319e11-204f-4c71-8666-a7049487872e"><enum>(4)</enum><text>by adding at the end the
following:</text>
<quoted-block changed="added" committee-id="SSHR00" display-inline="no-display-inline" id="iddd526b55-82e7-405d-ba8e-aa2b2223bb4e" reported-display-style="italic" style="OLC">
<paragraph id="id954f2bf3-1663-4929-a214-71e9f0dc78c2"><enum>(5)</enum><text>to encourage grantees
under this section to coordinate activities with other State officials
administering efforts to promote long-term care options that enable older
individuals to receive long-term care in home- and community-based settings, in
a manner responsive to the needs and preferences of older individuals and their
family caregivers;</text>
</paragraph><paragraph id="idc5d874db-953b-4e45-975a-4eb48755c845"><enum>(6)</enum><text>to encourage grantees
under this section to—</text>
<subparagraph id="idd4812c93-78a0-406d-b1e1-1933530a9cf5"><enum>(A)</enum><text>engage in activities that
support early detection and diagnosis of Alzheimer’s disease and related
disorders;</text>
</subparagraph><subparagraph id="id5f9346d4-de87-48bf-88de-a8dfdadcc1aa"><enum>(B)</enum><text>provide training to
medical personnel including hospital staff, emergency room personnel, home
health care workers and physician office staff, rehabilitation services
providers, and caregivers about how Alzheimer’s can affect behavior and impede
communication in medical and community settings;</text>
</subparagraph><subparagraph id="id29de1b32-07fc-4706-828f-ede08b07821b"><enum>(C)</enum><text>develop guidelines to
provide the medical community with up-to-date information about the best
methods of care for individuals with Alzheimer’s disease and related
disorders;</text>
</subparagraph><subparagraph id="id78ee72d1-70c3-4519-a1c4-740e249d8d3c"><enum>(D)</enum><text>inform community
physicians about available resources to assist them in detecting and managing
Alzheimer’s disease and related disorders; and</text>
</subparagraph><subparagraph id="idd5a13e99-015e-4158-a031-a0c270fa20c9"><enum>(E)</enum><text>raise awareness among
community physicians about the availability of community-based organizations
which can assist individuals with Alzheimer’s disease and related disorders and
their caregivers;</text>
</subparagraph></paragraph><paragraph id="id5d05f9fe-7174-435a-97b4-07f77f8017ab"><enum>(7)</enum><text>to encourage grantees
under this section to engage in activities that use findings from
evidence-based research on service models and techniques to support individuals
with Alzheimer’s disease and related disorders and their caregivers;</text>
</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id97711997-d09d-4bb1-b983-707bc0b866b7"><enum>(8)</enum><text>to encourage grantees
under this section to incorporate best practices for effectively serving
individuals with Alzheimer’s disease and related disorders in community-based
settings into ongoing State systems change and long-term care activities;
and</text>
</paragraph><paragraph id="ID631fc598252e4853b160fb45d8b927d3"><enum>(9)</enum><text>to encourage grantees to
coordinate with Aging and Disability Resource Centers or other single point of
entry
systems.</text>
</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
</paragraph></subsection></section>Amend the title so as to read:
A bill to amend the Public Health Service Act to fund breakthroughs in
Alzheimer's disease research while providing more help to caregivers and
increasing public and provider awareness about steps that may be taken to
respond rapidly to breakthroughs in prevention, early detection, and
management, about cognitive health, Alzheimer's disease, and other dementias
related to aging.
.
August 3, 2007
Reported with an amendment and an amendment to the
title